<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36552768</PMID><DateCompleted><Year>2022</Year><Month>12</Month><Day>26</Day></DateCompleted><DateRevised><Year>2023</Year><Month>01</Month><Day>15</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2073-4409</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>24</Issue><PubDate><Year>2022</Year><Month>Dec</Month><Day>10</Day></PubDate></JournalIssue><Title>Cells</Title><ISOAbbreviation>Cells</ISOAbbreviation></Journal><ArticleTitle>Development of a Nanoparticle-Based Approach for the Blood-Brain Barrier Passage in a Murine Model of Amyotrophic Lateral Sclerosis.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">4003</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/cells11244003</ELocationID><Abstract><AbstractText>The development of nanoparticles (NPs) to enable the passage of drugs across blood-brain barrier (BBB) represents one of the main challenges in neuropharmacology. In recent years, NPs that are able to transport drugs and interact with brain endothelial cells have been tested. Here, we investigated whether the functionalization of avidin-nucleic-acid-nanoassembly (ANANAS) with apolipoprotein E (ApoE) would allow BBB passage in the SOD1<sup>G93A</sup> mouse model of amyotrophic lateral sclerosis. Our results demonstrated that ANANAS was able to transiently cross BBB to reach the central nervous system (CNS), and ApoE did not enhance this property. Next, we investigated if ANANAS could improve CNS drug delivery. To this aim, the steroid dexamethasone was covalently linked to ANANAS through an acid-reversible hydrazone bond. Our data showed that the steroid levels in CNS tissues of SOD1<sup>G93A</sup> mice treated with nanoformulation were below the detection limit. This result demonstrates that the passage of BBB is not sufficient to guarantee the release of the cargo in CNS and that a different strategy for drug tethering should be devised. The present study furthermore highlights that NPs can be useful in improving the passage through biological barriers but may limit the interaction of the therapeutic compound with the specific target.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Violatto</LastName><ForeName>Martina Bruna</ForeName><Initials>MB</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Pharmacology, Istituto di Ricerche Farmacologiche "Mario Negri" IRCCS, 20133 Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pasetto</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Pharmacology, Istituto di Ricerche Farmacologiche "Mario Negri" IRCCS, 20133 Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Casarin</LastName><ForeName>Elisabetta</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Ananas Nanotech S.r.l., 35131 Padua, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tondello</LastName><ForeName>Camilla</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Pharmaceutical and Pharmacological Sciences, University of Padova, 35122 Padua, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Pharmazentrum Frankfurt/ZAFES, Goethe University Hospital Frankfurt, 60596 Frankfurt am Main, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schiavon</LastName><ForeName>Elisa</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Pharmaceutical and Pharmacological Sciences, University of Padova, 35122 Padua, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Talamini</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Pharmacology, Istituto di Ricerche Farmacologiche "Mario Negri" IRCCS, 20133 Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marchini</LastName><ForeName>Gloria</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Pharmacology, Istituto di Ricerche Farmacologiche "Mario Negri" IRCCS, 20133 Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cagnotto</LastName><ForeName>Alfredo</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Pharmacology, Istituto di Ricerche Farmacologiche "Mario Negri" IRCCS, 20133 Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morelli</LastName><ForeName>Annalisa</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-9009-6901</Identifier><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Pharmacology, Istituto di Ricerche Farmacologiche "Mario Negri" IRCCS, 20133 Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lanno</LastName><ForeName>Alessia</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-3473-8877</Identifier><AffiliationInfo><Affiliation>Department of Environmental Health Sciences, Istituto di Ricerche Farmacologiche "Mario Negri" IRCCS, 20133 Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Passoni</LastName><ForeName>Alice</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-6003-5932</Identifier><AffiliationInfo><Affiliation>Department of Environmental Health Sciences, Istituto di Ricerche Farmacologiche "Mario Negri" IRCCS, 20133 Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bigini</LastName><ForeName>Paolo</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Pharmacology, Istituto di Ricerche Farmacologiche "Mario Negri" IRCCS, 20133 Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morpurgo</LastName><ForeName>Margherita</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-8767-1995</Identifier><AffiliationInfo><Affiliation>Department of Pharmaceutical and Pharmacological Sciences, University of Padova, 35122 Padua, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bonetto</LastName><ForeName>Valentina</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Pharmacology, Istituto di Ricerche Farmacologiche "Mario Negri" IRCCS, 20133 Milan, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>12</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Cells</MedlineTA><NlmUniqueID>101600052</NlmUniqueID><ISSNLinking>2073-4409</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D000072105">Superoxide Dismutase-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004364">Pharmaceutical Preparations</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001812" MajorTopicYN="N">Blood-Brain Barrier</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072105" MajorTopicYN="N">Superoxide Dismutase-1</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D042783" MajorTopicYN="N">Endothelial Cells</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004364" MajorTopicYN="N">Pharmaceutical Preparations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053758" MajorTopicYN="Y">Nanoparticles</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Nanomedicine</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">blood&#x2013;brain barrier</Keyword><Keyword MajorTopicYN="N">pharmacology</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>11</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>12</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>12</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>12</Month><Day>23</Day><Hour>1</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>12</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>12</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36552768</ArticleId><ArticleId IdType="pmc">PMC9776960</ArticleId><ArticleId IdType="doi">10.3390/cells11244003</ArticleId><ArticleId IdType="pii">cells11244003</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Islam Y., Leach A.G., Smith J., Pluchino S., Coxon C.R., Sivakumaran M., Downing J., Fatokun A.A., Teixid&#xf2; M., Ehtezazi T. Physiological and Pathological Factors Affecting Drug Delivery to the Brain by Nanoparticles. Adv. Sci. 2021;8:2002085. doi: 10.1002/advs.202002085.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/advs.202002085</ArticleId><ArticleId IdType="pmc">PMC8188209</ArticleId><ArticleId IdType="pubmed">34105297</ArticleId></ArticleIdList></Reference><Reference><Citation>De Vries H.E., Kooij G., Frenkel D., Georgopoulos S., Monsonego A., Janigro D. Inflammatory Events at Blood-Brain Barrier in Neuroinflammatory and Neurodegenerative Disorders: Implications for Clinical Disease. Epilepsia. 2012;53((Suppl. 6)):45&#x2013;52. doi: 10.1111/j.1528-1167.2012.03702.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1528-1167.2012.03702.x</ArticleId><ArticleId IdType="pmc">PMC4853914</ArticleId><ArticleId IdType="pubmed">23134495</ArticleId></ArticleIdList></Reference><Reference><Citation>Garbuzova-Davis S., Sanberg P.R. Blood-CNS Barrier Impairment in ALS Patients versus an Animal Model. Front. Cell. Neurosci. 2014;8:21. doi: 10.3389/fncel.2014.00021.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2014.00021</ArticleId><ArticleId IdType="pmc">PMC3910123</ArticleId><ArticleId IdType="pubmed">24550780</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu F.-D., Hu Y.-J., Yu L., Zhou X.-G., Wu J.-M., Tang Y., Qin D.-L., Fan Q.-Z., Wu A.-G. Nanoparticles: A Hope for the Treatment of Inflammation in CNS. Front. Pharmacol. 2021;12:683935. doi: 10.3389/fphar.2021.683935.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2021.683935</ArticleId><ArticleId IdType="pmc">PMC8187807</ArticleId><ArticleId IdType="pubmed">34122112</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang G.Y., Rayner S.L., Chung R., Shi B.Y., Liang X.J. Advances in Nanotechnology-Based Strategies for the Treatments of Amyotrophic Lateral Sclerosis. Mater. Today Bio. 2020;6:100055. doi: 10.1016/j.mtbio.2020.100055.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mtbio.2020.100055</ArticleId><ArticleId IdType="pmc">PMC7280770</ArticleId><ArticleId IdType="pubmed">32529183</ArticleId></ArticleIdList></Reference><Reference><Citation>Duan X., Li Y. Physicochemical Characteristics of Nanoparticles Affect Circulation, Biodistribution, Cellular Internalization, and Trafficking. Small. 2013;9:1521&#x2013;1532. doi: 10.1002/smll.201201390.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/smll.201201390</ArticleId><ArticleId IdType="pubmed">23019091</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahley R.W. Central Nervous System Lipoproteins: ApoE and Regulation of Cholesterol Metabolism. Arterioscler. Thromb. Vasc. Biol. 2016;36:1305&#x2013;1315. doi: 10.1161/ATVBAHA.116.307023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/ATVBAHA.116.307023</ArticleId><ArticleId IdType="pmc">PMC4942259</ArticleId><ArticleId IdType="pubmed">27174096</ArticleId></ArticleIdList></Reference><Reference><Citation>Re F., Cambianica I., Zona C., Sesana S., Gregori M., Rigolio R., La Ferla B., Nicotra F., Forloni G., Cagnotto A., et al. Functionalization of Liposomes with ApoE-Derived Peptides at Different Density Affects Cellular Uptake and Drug Transport across a Blood-Brain Barrier Model. Nanomedicine. 2011;7:551&#x2013;559. doi: 10.1016/j.nano.2011.05.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nano.2011.05.004</ArticleId><ArticleId IdType="pubmed">21658472</ArticleId></ArticleIdList></Reference><Reference><Citation>Morpurgo M., Radu A., Bayer E.A., Wilchek M. DNA Condensation by High-Affinity Interaction with Avidin. J. Mol. Recognit. 2004;17:558&#x2013;566. doi: 10.1002/jmr.689.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmr.689</ArticleId><ArticleId IdType="pubmed">15386619</ArticleId></ArticleIdList></Reference><Reference><Citation>Pignatto M., Realdon N., Morpurgo M. Optimized Avidin Nucleic Acid Nanoassemblies by a Tailored PEGylation Strategy and Their Application as Molecular Amplifiers in Detection. Bioconjug. Chem. 2010;21:1254&#x2013;1263. doi: 10.1021/bc100044u.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/bc100044u</ArticleId><ArticleId IdType="pubmed">20527874</ArticleId></ArticleIdList></Reference><Reference><Citation>Roncato F., Rruga F., Porc&#xf9; E., Casarin E., Ronca R., Maccarinelli F., Realdon N., Basso G., Alon R., Viola G., et al. Improvement and Extension of Anti-EGFR Targeting in Breast Cancer Therapy by Integration with the Avidin-Nucleic-Acid-Nano-Assemblies. Nat. Commun. 2018;9:4070. doi: 10.1038/s41467-018-06602-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-018-06602-6</ArticleId><ArticleId IdType="pmc">PMC6172284</ArticleId><ArticleId IdType="pubmed">30287819</ArticleId></ArticleIdList></Reference><Reference><Citation>Violatto M.B., Casarin E., Talamini L., Russo L., Baldan S., Tondello C., Messmer M., Hintermann E., Rossi A., Passoni A., et al. Dexamethasone Conjugation to Biodegradable Avidin-Nucleic-Acid-Nano-Assemblies Promotes Selective Liver Targeting and Improves Therapeutic Efficacy in an Autoimmune Hepatitis Murine Model. ACS Nano. 2019;13:4410&#x2013;4423. doi: 10.1021/acsnano.8b09655.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsnano.8b09655</ArticleId><ArticleId IdType="pubmed">30883091</ArticleId></ArticleIdList></Reference><Reference><Citation>Bigini P., Previdi S., Casarin E., Silvestri D., Violatto M.B., Facchin S., Sitia L., Rosato A., Zuccolotto G., Realdon N., et al. In Vivo Fate of Avidin-Nucleic Acid Nanoassemblies as Multifunctional Diagnostic Tools. ACS Nano. 2014;8:175&#x2013;187. doi: 10.1021/nn402669w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/nn402669w</ArticleId><ArticleId IdType="pubmed">24328174</ArticleId></ArticleIdList></Reference><Reference><Citation>Garbuzova-Davis S., Saporta S., Haller E., Kolomey I., Bennett S.P., Potter H., Sanberg P.R. Evidence of Compromised Blood-Spinal Cord Barrier in Early and Late Symptomatic SOD1 Mice Modeling ALS. PLoS ONE. 2007;2:e1205. doi: 10.1371/journal.pone.0001205.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0001205</ArticleId><ArticleId IdType="pmc">PMC2075163</ArticleId><ArticleId IdType="pubmed">18030339</ArticleId></ArticleIdList></Reference><Reference><Citation>Ongaro A., Violatto M.B., Casarin E., Pellerani I., Marchini G., Ribaudo G., Salmona M., Carbone M., Passoni A., Gnodi E., et al. The Mode of Dexamethasone Decoration Influences Avidin-Nucleic-Acid-Nano-Assembly Organ Biodistribution and in Vivo Drug Persistence. Nanomedicine. 2022;40:102497. doi: 10.1016/j.nano.2021.102497.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nano.2021.102497</ArticleId><ArticleId IdType="pubmed">34838993</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonz&#xe1;lez Deniselle M.C., Gonz&#xe1;lez S.L., De Nicola A.F. Cellular Basis of Steroid Neuroprotection in the Wobbler Mouse, a Genetic Model of Motoneuron Disease. Cell. Mol. Neurobiol. 2001;21:237&#x2013;254. doi: 10.1023/A:1010943104315.</Citation><ArticleIdList><ArticleId IdType="doi">10.1023/A:1010943104315</ArticleId><ArticleId IdType="pubmed">11569536</ArticleId></ArticleIdList></Reference><Reference><Citation>Tokuda E., Watanabe S., Okawa E., Ono S. Regulation of Intracellular Copper by Induction of Endogenous Metallothioneins Improves the Disease Course in a Mouse Model of Amyotrophic Lateral Sclerosis. Neurotherapeutics. 2015;12:461&#x2013;476. doi: 10.1007/s13311-015-0346-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-015-0346-x</ArticleId><ArticleId IdType="pmc">PMC4404437</ArticleId><ArticleId IdType="pubmed">25761970</ArticleId></ArticleIdList></Reference><Reference><Citation>Green N.M. Advances in Protein Chemistry. Volume 29. Elsevier; Amsterdam, The Netherlands: 1975. Avidin; pp. 85&#x2013;133.</Citation><ArticleIdList><ArticleId IdType="pubmed">237414</ArticleId></ArticleIdList></Reference><Reference><Citation>Sims G.E.C., Snape T.J. A Method for the Estimation of Polyethylene Glycol in Plasma Protein Fractions. Anal. Biochem. 1980;107:60&#x2013;63. doi: 10.1016/0003-2697(80)90492-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0003-2697(80)90492-3</ArticleId><ArticleId IdType="pubmed">7435960</ArticleId></ArticleIdList></Reference><Reference><Citation>Lauranzano E., Pozzi S., Pasetto L., Stucchi R., Massignan T., Paolella K., Mombrini M., Nardo G., Lunetta C., Corbo M., et al. Peptidylprolyl Isomerase A Governs TARDBP Function and Assembly in Heterogeneous Nuclear Ribonucleoprotein Complexes. Brain. 2015;138:974&#x2013;991. doi: 10.1093/brain/awv005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awv005</ArticleId><ArticleId IdType="pubmed">25678563</ArticleId></ArticleIdList></Reference><Reference><Citation>Filareti M., Luotti S., Pasetto L., Pignataro M., Paolella K., Messina P., Pupillo E., Filosto M., Lunetta C., Mandrioli J., et al. Decreased Levels of Foldase and Chaperone Proteins Are Associated with an Early-Onset Amyotrophic Lateral Sclerosis. Front. Mol. Neurosci. 2017;10:99. doi: 10.3389/fnmol.2017.00099.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2017.00099</ArticleId><ArticleId IdType="pmc">PMC5382314</ArticleId><ArticleId IdType="pubmed">28428745</ArticleId></ArticleIdList></Reference><Reference><Citation>Luotti S., Pasetto L., Porcu L., Torri V., Elezgarai S.R., Pantalone S., Filareti M., Corbo M., Lunetta C., Mora G., et al. Diagnostic and Prognostic Values of PBMC Proteins in Amyotrophic Lateral Sclerosis. Neurobiol. Dis. 2020;139:104815. doi: 10.1016/j.nbd.2020.104815.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2020.104815</ArticleId><ArticleId IdType="pubmed">32087285</ArticleId></ArticleIdList></Reference><Reference><Citation>Damonte G., Salis A., Rossi L., Magnani M., Benatti U. High Throughput HPLC-ESI-MS Method for the Quantitation of Dexamethasone in Blood Plasma. J. Pharm. Biomed. Anal. 2007;43:376&#x2013;380. doi: 10.1016/j.jpba.2006.06.042.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpba.2006.06.042</ArticleId><ArticleId IdType="pubmed">16887316</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan Y., Zhou X., Li J., Ye S., Ji X., Li L., Zhou T., Lu W. Development and Validation of a Highly Sensitive LC-MS/MS Method for the Determination of Dexamethasone in Nude Mice Plasma and Its Application to a Pharmacokinetic Study: Quantitative Determination of Dexamethasone in Nude Mouse Plasma. Biomed. Chromatogr. 2015;29:578&#x2013;583. doi: 10.1002/bmc.3316.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/bmc.3316</ArticleId><ArticleId IdType="pubmed">25165023</ArticleId></ArticleIdList></Reference><Reference><Citation>Pasetto L., Pozzi S., Castelnovo M., Basso M., Estevez A.G., Fumagalli S., De Simoni M.G., Castellaneta V., Bigini P., Restelli E., et al. Targeting Extracellular Cyclophilin A Reduces Neuroinflammation and Extends Survival in a Mouse Model of Amyotrophic Lateral Sclerosis. J. Neurosci. 2017;37:1413&#x2013;1427. doi: 10.1523/JNEUROSCI.2462-16.2016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2462-16.2016</ArticleId><ArticleId IdType="pmc">PMC6705677</ArticleId><ArticleId IdType="pubmed">28011744</ArticleId></ArticleIdList></Reference><Reference><Citation>Pardridge W.M. The Blood-Brain Barrier: Bottleneck in Brain Drug Development. Neurotherapeutics. 2005;2:3&#x2013;14. doi: 10.1602/neurorx.2.1.3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1602/neurorx.2.1.3</ArticleId><ArticleId IdType="pmc">PMC539316</ArticleId><ArticleId IdType="pubmed">15717053</ArticleId></ArticleIdList></Reference><Reference><Citation>Salvati A., Pitek A.S., Monopoli M.P., Prapainop K., Bombelli F.B., Hristov D.R., Kelly P.M., &#xc5;berg C., Mahon E., Dawson K.A. Transferrin-Functionalized Nanoparticles Lose Their Targeting Capabilities When a Biomolecule Corona Adsorbs on the Surface. Nat. Nanotechnol. 2013;8:137&#x2013;143. doi: 10.1038/nnano.2012.237.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nnano.2012.237</ArticleId><ArticleId IdType="pubmed">23334168</ArticleId></ArticleIdList></Reference><Reference><Citation>Cox A., Andreozzi P., Dal Magro R., Fiordaliso F., Corbelli A., Talamini L., Chinello C., Raimondo F., Magni F., Tringali M., et al. Evolution of Nanoparticle Protein Corona across the Blood&#x2013;Brain Barrier. ACS Nano. 2018;12:7292&#x2013;7300. doi: 10.1021/acsnano.8b03500.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsnano.8b03500</ArticleId><ArticleId IdType="pubmed">29953205</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeo E.L.L., Cheah J.U.-J., Thong P.S.P., Soo K.C., Kah J.C.Y. Gold Nanorods Coated with Apolipoprotein E Protein Corona for Drug Delivery. ACS Appl. Nano Mater. 2019;2:6220&#x2013;6229. doi: 10.1021/acsanm.9b01196.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsanm.9b01196</ArticleId></ArticleIdList></Reference><Reference><Citation>Kong W.-J., Liu J., Jiang J.-D. Human Low-Density Lipoprotein Receptor Gene and Its Regulation. J. Mol. Med. 2006;84:29&#x2013;36. doi: 10.1007/s00109-005-0717-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00109-005-0717-6</ArticleId><ArticleId IdType="pubmed">16292665</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang B., Sun X., Mei H., Wang Y., Liao Z., Chen J., Zhang Q., Hu Y., Pang Z., Jiang X. LDLR-Mediated Peptide-22-Conjugated Nanoparticles for Dual-Targeting Therapy of Brain Glioma. Biomaterials. 2013;34:9171&#x2013;9182. doi: 10.1016/j.biomaterials.2013.08.039.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biomaterials.2013.08.039</ArticleId><ArticleId IdType="pubmed">24008043</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J., Basak J.M., Holtzman D.M. The Role of Apolipoprotein E in Alzheimer&#x2019;s Disease. Neuron. 2009;63:287&#x2013;303. doi: 10.1016/j.neuron.2009.06.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2009.06.026</ArticleId><ArticleId IdType="pmc">PMC3044446</ArticleId><ArticleId IdType="pubmed">19679070</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhong Z., Deane R., Ali Z., Parisi M., Shapovalov Y., O&#x2019;Banion M.K., Stojanovic K., Sagare A., Boillee S., Cleveland D.W., et al. ALS-Causing SOD1 Mutants Generate Vascular Changes Prior to Motor Neuron Degeneration. Nat. Neurosci. 2008;11:420&#x2013;422. doi: 10.1038/nn2073.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn2073</ArticleId><ArticleId IdType="pmc">PMC2895310</ArticleId><ArticleId IdType="pubmed">18344992</ArticleId></ArticleIdList></Reference><Reference><Citation>Jablonski M.R., Jacob D.A., Campos C., Miller D.S., Maragakis N.J., Pasinelli P., Trotti D. Selective Increase of Two ABC Drug Efflux Transporters at the Blood&#x2013;Spinal Cord Barrier Suggests Induced Pharmacoresistance in ALS. Neurobiol. Dis. 2012;47:194&#x2013;200. doi: 10.1016/j.nbd.2012.03.040.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2012.03.040</ArticleId><ArticleId IdType="pmc">PMC3367047</ArticleId><ArticleId IdType="pubmed">22521463</ArticleId></ArticleIdList></Reference><Reference><Citation>Werdelin L., Boysen G., Jensen T.S., Mogensen P. Immunosuppressive Treatment of Patients with Amyotrophic Lateral Sclerosis. Acta Neurol. Scand. 1990;82:132&#x2013;134. doi: 10.1111/j.1600-0404.1990.tb01602.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-0404.1990.tb01602.x</ArticleId><ArticleId IdType="pubmed">2256442</ArticleId></ArticleIdList></Reference><Reference><Citation>Fournier C.N., Schoenfeld D., Berry J.D., Cudkowicz M.E., Chan J., Quinn C., Brown R.H., Salameh J.S., Tansey M.G., Beers D.R., et al. An Open Label Study of a Novel Immunosuppression Intervention for the Treatment of Amyotrophic Lateral Sclerosis. Amyotroph. Lateral Scler. Frontotemporal Degener. 2018;19:242&#x2013;249. doi: 10.1080/21678421.2017.1421666.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2017.1421666</ArticleId><ArticleId IdType="pubmed">29308669</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Es M.A., Van Eijk R.P.A., Bunte T.M., Van Den Berg L.H. A Placebo-Controlled Trial to Investigate the Safety and Efficacy of Penicillin G/Hydrocortisone in Patients with ALS (PHALS Trial) Amyotroph. Lateral Scler. Frontotemporal Degener. 2020;21:584&#x2013;592. doi: 10.1080/21678421.2020.1788093.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2020.1788093</ArticleId><ArticleId IdType="pubmed">32627599</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans M.C., Gaillard P.J., de Boer M., Appeldoorn C., Dorland R., Sibson N.R., Turner M.R., Anthony D.C., Stolp H.B. CNS-Targeted Glucocorticoid Reduces Pathology in Mouse Model of Amyotrophic Lateral Sclerosis. Acta Neuropathol. Commun. 2014;2:66. doi: 10.1186/2051-5960-2-66.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/2051-5960-2-66</ArticleId><ArticleId IdType="pmc">PMC4229735</ArticleId><ArticleId IdType="pubmed">24923195</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>